Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin plus intensive therapy versus intensive therapy alone in type 2 diabetes
ChiCTR1900022412Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The Second Hospital of Hebei Medical University. Primary endpoints: 1,5-anhydroglucitol, glycosylated serum albumin and 1 more. Planned start May 2019; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900022412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022412.